Plus Therapeutics, INC 8-K filings

Plus Therapeutics, Inc. has entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $17.35 million in common stock via an at-the-market offering.

Plus Therapeutics stockholders approved all proposals at the 2026 Annual Meeting, including director elections and the 2020 Stock Incentive Plan amendment.

Plus Therapeutics reports Q1 2026 financial results, highlighting CNSide commercial progress and REYOBIQ clinical milestones.

Plus Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement following a recent reverse stock split.

Plus Therapeutics, Inc. announced the appointment of Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026, bringing extensive experience in pharmaceutical development.

Plus Therapeutics announced its drug REYOBIQ has received Orphan Drug Designation from the FDA for treating pediatric malignant gliomas, a rare and aggressive brain cancer.

Plus Therapeutics, Inc. announced the appointment of Ronald A. Andrews to its Board of Directors, filling a vacancy left by Dr. Robert Lenk's resignation.

Plus Therapeutics, Inc. announced the date for its 2026 Annual Meeting of Stockholders and revised deadlines for shareholder proposals and director nominations.

Plus Therapeutics provides a corporate update highlighting significant progress in its CNSide diagnostic and REYOBIQ radiotherapeutic platforms, including positive clinical trial data and commercial expansion plans.

Plus Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of common stock and warrants, raising approximately $13.3 million in net proceeds for working capital and general corporate purposes.

Plus Therapeutics, Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, pushing the deadline to May 11, 2026.

Plus Therapeutics reported increased cash and investments, regained Nasdaq compliance, and launched its CNSide CSF diagnostics platform with national coverage.

Plus Therapeutics, Inc. has entered into a new 10-year lease for approximately 11,370 rentable square feet of lab and office space in Houston, Texas, with an anticipated commencement date of November 1, 2026.

Plus Therapeutics, Inc. announced it has regained compliance with Nasdaq's Market Value of Listed Securities and Stockholders' Equity standards, extending its bid price compliance deadline.

Plus Therapeutics reports improved Q2 2025 financial results, driven by non-operating income, alongside significant advancements in its REYOBIQ clinical trials and the commercial launch of its CNSide diagnostic platform.

Plus Therapeutics, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement and met an alternative listing threshold, awaiting formal confirmation.

Plus Therapeutics, Inc. received conditional approval for continued Nasdaq listing after addressing non-compliance with equity and bid price requirements.

Plus Therapeutics, Inc. stockholders approved the election of directors, a potential $51 million stock issuance, and discretionary authority for a reverse stock split at their 2025 Annual Meeting.

Plus Therapeutics, Inc. has dismissed BDO USA, P.C. as its independent registered public accounting firm and engaged CBIZ CPAs P.C., following BDO's reports that included a going concern explanatory paragraph and a previously disclosed material weakness in internal controls.

Plus Therapeutics, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, providing the company with access to up to $50 million in capital through common stock sales over a 36-month period.

Plus Therapeutics, Inc. has entered into a letter agreement with purchasers from its March 2025 private placement to substantially reduce potential share dilution and amend warrant terms.

Plus Therapeutics, Inc. has received a delisting notice from Nasdaq due to its failure to meet the minimum stockholders' equity requirement, prompting the company to plan an appeal.

Plus Therapeutics reported a significantly improved cash position in the first quarter of 2025, fueled by a $15 million private placement and a $2 million grant advance, as it continues to progress its REYOBIQ clinical trials and prepare for the CNSide platform launch, despite a widened net loss of $17.4 million.

Plus Therapeutics, Inc. has received a notice from Nasdaq regarding its non-compliance with listing rules due to the delayed filing of its first-quarter 2025 financial report, though the notice has no immediate effect on its stock listing.

Plus Therapeutics, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its common stock price has fallen below $1.00 for 30 consecutive business days.

Plus Therapeutics' stockholders approved an increase in authorized common stock and granted the board authority to execute a reverse stock split at a ratio between 1-for-25 and 1-for-250.

Plus Therapeutics appoints Kyle Guse to its Board of Directors, filling the vacancy left by Greg Petersen's resignation.

Plus Therapeutics announces its Q4 and full year 2024 financial results, highlighting a $15 million financing round and the upcoming commercial launch of its CNSide diagnostic platform.

Plus Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement following a private placement.

Plus Therapeutics secures $15 million in a private placement, including an agreement to repurchase outstanding convertible notes, aiming to regain Nasdaq compliance.